A pretest-posttest pilot study for the development and preliminary validation of a tool for the clinical assessment of radioiodine induced sialadenitis.
Thyroid cancer
radioiodine therapy
salivary gland dysfunction
sialadenitis
sialadenitis assessment
Journal
SAGE open medicine
ISSN: 2050-3121
Titre abrégé: SAGE Open Med
Pays: England
ID NLM: 101624744
Informations de publication
Date de publication:
2021
2021
Historique:
received:
15
02
2021
accepted:
06
08
2021
entrez:
6
9
2021
pubmed:
7
9
2021
medline:
7
9
2021
Statut:
epublish
Résumé
The clinical assessment of radioiodine-induced sialadenitis is relied on the observer-defined toxicity grading model. However, this model has significant limitations, the major one being the lack of systematic assessment based on objective criteria. The main aim of this study was the development and testing of an assessment tool which could examine the severity of post-irradiation sialadenitis. The development of the Sialadenitis Assessment Tool proceeded through three phases. The first and second phases included a literature review and the development of the tool which derived from the review, respectively. The third phase involved a pilot testing of the Assessment Tool to a sample of 34 patients undergoing I According to the Cohen's kappa test, the Sialadenitis Assessment Tool is a reliable tool for the assessment of sialadenitis (Cohen's κ = 1). The concurrent and internal validity tests showed a tendency of association with most variables (p < 0.001) in the DIRIX and EORTC QLQ-HN35 scales. Preliminary evidence show that Sialadenitis Assessment Tool is a valid and reliable tool to assess radioiodine-induced sialadenitis in patients undergoing I
Identifiants
pubmed: 34484788
doi: 10.1177/20503121211042211
pii: 10.1177_20503121211042211
pmc: PMC8414619
doi:
Types de publication
Journal Article
Langues
eng
Pagination
20503121211042211Informations de copyright
© The Author(s) 2021.
Déclaration de conflit d'intérêts
Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Bull World Health Organ. 2001;79(4):373-4
pubmed: 11357217
Asia Pac J Oncol Nurs. 2017 Oct-Dec;4(4):319-322
pubmed: 28966960
Thyroid. 2015 Jul;25(7):834-8
pubmed: 25860842
Head Neck. 2016 Jan;38(1):51-8
pubmed: 24995941
Oral Dis. 2006 Sep;12(5):476-9
pubmed: 16910918
J Oral Maxillofac Surg. 2015 Mar;73(3):475-81
pubmed: 25544300
J Nucl Med. 2009 Oct;50(10):1605-10
pubmed: 19759114
Clin Otolaryngol. 2016 Jun;41(3):259-75
pubmed: 26264703
Thyroid. 2003 Mar;13(3):265-71
pubmed: 12729475
Nucl Med Commun. 2013 Aug;34(8):777-86
pubmed: 23708871
Sci Rep. 2019 Mar 5;9(1):3616
pubmed: 30837617
Oral Dis. 2006 May;12(3):297-300
pubmed: 16700739
Biomed Res Int. 2016;2016:4376720
pubmed: 26989683
Eur J Oncol Nurs. 2017 Apr;27:1-8
pubmed: 28279391
Case Rep Dent. 2012;2012:615375
pubmed: 22888457
Ann Nucl Med. 2004 Jun;18(4):345-9
pubmed: 15359929
Head Neck. 2012 Feb;34(2):168-74
pubmed: 21416547
Laryngoscope. 2016 Jan;126(1):93-9
pubmed: 26256263
Head Neck. 2011 May;33(5):686-90
pubmed: 21484917
Laryngoscope. 2015 Jun;125(6):1340-4
pubmed: 25424183
Support Care Cancer. 2008 Feb;16(2):171-9
pubmed: 17618467
J Nucl Med. 2005 Feb;46(2):261-6
pubmed: 15695785
Radiother Oncol. 2011 Jan;98(1):48-50
pubmed: 21044803
Eur J Nucl Med Mol Imaging. 2011 May;38 Suppl 1:S48-56
pubmed: 21484380
J Nucl Med. 2010 Apr;51(4):618-23
pubmed: 20237029
Front Public Health. 2018 Jun 11;6:149
pubmed: 29942800
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
Eur Arch Otorhinolaryngol. 2013 May;270(6):1941-6
pubmed: 23223886
J Clin Epidemiol. 2012 Jul;65(7):778-84
pubmed: 22560852
Laryngoscope. 2014 Apr;124(4):869-74
pubmed: 23929724
J Nucl Med. 2001 May;42(5):738-43
pubmed: 11337569
Eur J Nucl Med Mol Imaging. 2010 Dec;37(12):2298-306
pubmed: 20625723